A Prospective, Comparative, Assessor Blind, Randomized, Multicentric Phase III study to compare the safety and efficacy of Ranibizumab of Intas Biopharmaceuticals Ltd. in comparison with Lucentis of Novartis in patients of wet AMD (Age related Macular Degeneration).

Trial Profile

A Prospective, Comparative, Assessor Blind, Randomized, Multicentric Phase III study to compare the safety and efficacy of Ranibizumab of Intas Biopharmaceuticals Ltd. in comparison with Lucentis of Novartis in patients of wet AMD (Age related Macular Degeneration).

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors Intas Biopharmaceuticals
  • Most Recent Events

    • 15 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top